Skip to main content

Drug Interactions between erdafitinib and palovarotene

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

erdafitinib palovarotene

Applies to: erdafitinib and palovarotene

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs. In vitro, erdafitinib has been shown to be a time-dependent inhibitor as well as inducer of CYP450 3A4. However, no pharmacokinetic data are available from drug interaction studies.

MANAGEMENT: Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.

Drug and food interactions

Major

palovarotene food

Applies to: palovarotene

Grapefruit, pomelo, and juices or supplements containing these fruits may increase the blood levels of palovarotene, which may increase the risk and/or severity of side effects such as dry skin, dry lips, hair loss, skin rash, itching, skin and nail infection, dry eyes, night blindness, depression, and mood changes. It may also increase the risk of a rare, but potentially serious, condition called pseudotumor cerebri caused by increased pressure in the brain. Palovarotene should be taken with food at approximately the same time each day. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.